Literature DB >> 35693995

Advanced proliferative diabetic retinopathy and macular edema in acromegaly: a case report and literature review.

Akiko Yuno1, Akemi Ikota1, Shigeki Koizumi1, Yasuo Mashio1, Hiroko Imaizumi2, Yutaka Sawamura3, Akira Shimatsu4.   

Abstract

We describe the multimodal management of a patient with proliferative diabetic retinopathy and diabetic macular edema associated with active acromegaly. A 61-year-old Japanese female who had had type 2 diabetic mellitus for > 10 years complained of deteriorated eyesight. She had distinct acromegalic features, and her visual acuity was 0.05 (right) and 0.4 (left) because of sub-capsular cataracts and proliferative diabetic retinopathy with macular edema. Anti-vascular endothelial growth factor treatments, cataract surgeries and retinal direct laser photocoagulation were performed together with gradual glycemic control with basal insulin to prevent worsening of the visual impairment. She was given an injection of a long-acting somatostatin analog (octreotide LAR) and began taking three bolus mealtime insulin shots with basal insulin beginning 1 month before undergoing a trans-sphenoidal adenomectomy. After this successful surgery, her blood glucose levels immediately decreased, and the rapid-acting insulin at mealtimes was discontinued with the observation of normal growth hormone and insulin-like growth factor (IGF)-1 levels, suggesting that her acromegaly was in remission. Her visual acuity improved without a worsening of diabetic retinopathy. Since the increased IGF-1 production in systemic circulation and local vitreous fluids may be one of the aggravating factors for diabetic retinopathy, our patient's acromegaly complicated with severe retinopathy presented an opportunity for multimodal management in close collaboration with an ophthalmologist, neurosurgeon, and endocrinologist. Our literature review revealed that the estimated prevalence of diabetic retinopathy in cases of acromegaly associated with diabetes mellitus is 12.5-42.9%. © The Japan Diabetes Society 2022.

Entities:  

Keywords:  Acromegaly; Growth hormone; Insulin-like growth factor 1; Proliferative diabetic retinopathy; Vascular endothelial growth factor

Year:  2022        PMID: 35693995      PMCID: PMC9174379          DOI: 10.1007/s13340-022-00571-4

Source DB:  PubMed          Journal:  Diabetol Int        ISSN: 2190-1678


  26 in total

1.  Essential role of growth hormone in ischemia-induced retinal neovascularization.

Authors:  L E Smith; J J Kopchick; W Chen; J Knapp; F Kinose; D Daley; E Foley; R G Smith; J M Schaeffer
Journal:  Science       Date:  1997-06-13       Impact factor: 47.728

Review 2.  Acromegaly.

Authors:  Annamaria Colao; Ludovica F S Grasso; Andrea Giustina; Shlomo Melmed; Philippe Chanson; Alberto M Pereira; Rosario Pivonello
Journal:  Nat Rev Dis Primers       Date:  2019-03-21       Impact factor: 52.329

3.  The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study.

Authors:  M B Grant; R N Mames; C Fitzgerald; K M Hazariwala; R Cooper-DeHoff; S Caballero; K S Estes
Journal:  Diabetes Care       Date:  2000-04       Impact factor: 19.112

4.  Vitreous levels of IGF-I, IGF binding protein 1, and IGF binding protein 3 in proliferative diabetic retinopathy: a case-control study.

Authors:  R Burgos; C Mateo; A Cantón; C Hernández; J Mesa; R Simó
Journal:  Diabetes Care       Date:  2000-01       Impact factor: 19.112

5.  Deterioration of visual acuity associated with growth hormone therapy in a child with extreme short stature and high hypermetropia.

Authors:  Wendy F Paterson; Brian Kelly; William Newman; Martin O Savage; Cecilia Camacho-Hubner; Gordon N Dutton; John Tolmie; Malcolm D C Donaldson
Journal:  Horm Res       Date:  2006-10-06

Review 6.  The role of growth hormone, insulin-like growth factor and somatostatin in diabetic retinopathy.

Authors:  Jennifer L Wilkinson-Berka; Christopher Wraight; George Werther
Journal:  Curr Med Chem       Date:  2006       Impact factor: 4.530

7.  Increased ocular levels of IGF-1 in transgenic mice lead to diabetes-like eye disease.

Authors:  Jesús Ruberte; Eduard Ayuso; Marc Navarro; Ana Carretero; Víctor Nacher; Virginia Haurigot; Mónica George; Cristina Llombart; Alba Casellas; Cristina Costa; Assumpció Bosch; Fatima Bosch
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

8.  Diabetic retinopathy in acromegaly.

Authors:  T Amemiya; M Toibana; M Hashimoto; F Oseko; H Imura
Journal:  Ophthalmologica       Date:  1978       Impact factor: 3.250

9.  Retinal changes mimicking diabetic retinopathy in two nondiabetic, growth hormone-treated patients.

Authors:  E A Koller; L Green; J M Gertner; M Bost; S N Malozowski
Journal:  J Clin Endocrinol Metab       Date:  1998-07       Impact factor: 5.958

10.  Diabetic retinopathy in acromegaly.

Authors:  Said Azzoug; Farida Chentli
Journal:  Indian J Endocrinol Metab       Date:  2014-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.